Gilead on track for first sofosbuvir filings following positive FUSION data
This article was originally published in Scrip
Executive Summary
Gilead Sciences saw a modest increase in its stock price on 19 February - closing up $0.68, or 1.6%, at $42.28 per share - after it reported superior sustained virologic response (SVR) rates for genotype 2 and hard-to-treat genotype 3 hepatitis C patients in the Phase III FUSION clinical trial for sofosbuvir.